Myriad Genetics (MYGN) Financials

$4.16 -0.17 (-3.93%)

Closing price 04:00 PM Eastern

Extended Trading

$4.17 +0.01 (+0.14%)

As of 07:19 PM Eastern

Annual Income Statements for Myriad Genetics

This table shows Myriad Genetics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-127	-263	-112
Consolidated Net Income / (Loss)	-127	-263	-112
Net Income / (Loss) Continuing Operations	-127	-263	-112
Total Pre-Tax Income	-124	-262	-141
Total Operating Income	-124	-257	-141
Total Gross Profit	585	517	476
Total Revenue	838	753	678
Operating Revenue	838	753	678
Total Cost of Revenue	252	236	202
Operating Cost of Revenue	252	236	202
Total Operating Expenses	709	774	617
Selling, General & Admin Expense	276	284	248
Marketing Expense	284	289	267
Research & Development Expense	113	89	85
Other Operating Expenses / (Income)	-21	113	0.00
Impairment Charge	57	0.00	17
Total Other Income / (Expense), net	0.00	-4.80	0.00
Interest Expense	2.80	2.90	3.20
Interest & Investment Income	1.70	2.50	2.60
Other Income / (Expense), net	1.10	-4.40	0.60
Income Tax Expense	3.80	1.10	-29
Basic Earnings per Share	($1.41)	($3.18)	($1.39)
Weighted Average Basic Shares Outstanding	90.60M	82.80M	80.60M
Diluted Earnings per Share	($1.41)	($3.18)	($1.39)
Weighted Average Diluted Shares Outstanding	90.60M	82.80M	80.60M
Weighted Average Basic & Diluted Shares Outstanding	91.31M	89.87M	81.22M

This table shows Myriad Genetics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-43	-22	-37	-26	-31	-61	-116	-55	-42	-35
Consolidated Net Income / (Loss)	-43	-22	-37	-26	-31	-61	-116	-55	-42	-35
Net Income / (Loss) Continuing Operations	-43	-22	-37	-26	-31	-61	-116	-55	-42	-35
Total Pre-Tax Income	-39	-21	-37	-26	-32	-61	-116	-53	-52	-44
Total Operating Income	-39	-20	-37	-28	-31	-60	-114	-52	-52	-45
Total Gross Profit	151	150	147	138	135	134	126	122	124	106
Total Revenue	211	213	212	202	197	192	184	181	178	156
Operating Revenue	211	213	212	202	197	192	184	181	178	156
Total Cost of Revenue	60	64	64	65	62	58	58	59	54	50
Operating Cost of Revenue	60	64	64	65	62	58	58	59	54	50
Total Operating Expenses	190	170	184	166	166	194	239	174	176	151
Selling, General & Admin Expense	-149	139	145	141	-145	136	141	152	-120	131
Research & Development Expense	33	29	27	25	21	24	21	23	23	21
Total Other Income / (Expense), net	-0.10	-1.20	-0.70	2.00	-0.90	-1.10	-2.40	-0.40	0.10	0.80
Interest Expense	0.70	0.80	0.80	0.50	0.90	1.00	0.50	0.50	0.90	0.80
Interest & Investment Income	0.30	0.40	0.40	0.60	0.70	0.60	0.50	0.70	1.00	1.10
Other Income / (Expense), net	0.30	-0.80	-0.30	1.90	-0.70	-0.70	-2.40	-0.60	-	0.50
Income Tax Expense	3.30	0.90	-0.50	0.10	-1.10	0.10	0.00	2.10	-9.80	-9.10
Basic Earnings per Share	($0.47)	($0.24)	($0.41)	($0.29)	($0.34)	($0.75)	($1.42)	($0.67)	($0.52)	($0.43)
Weighted Average Basic Shares Outstanding	90.60M	90.90M	90.60M	89.90M	82.80M	81.90M	81.70M	81.30M	80.60M	80.70M
Diluted Earnings per Share	($0.47)	($0.24)	($0.41)	($0.29)	($0.34)	($0.75)	($1.42)	($0.67)	($0.52)	($0.43)
Weighted Average Diluted Shares Outstanding	90.60M	90.90M	90.60M	89.90M	82.80M	81.90M	81.70M	81.30M	80.60M	80.70M
Weighted Average Basic & Diluted Shares Outstanding	91.31M	91.04M	90.82M	90.51M	89.87M	82.20M	81.88M	81.56M	81.22M	81.03M

This table details how cash moves in and out of Myriad Genetics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	-29	75	-192
Net Cash From Operating Activities	-8.70	-111	-106
Net Cash From Continuing Operating Activities	-8.70	-111	-106
Net Income / (Loss) Continuing Operations	-127	-263	-112
Consolidated Net Income / (Loss)	-127	-263	-112
Depreciation Expense	61	62	53
Non-Cash Adjustments To Reconcile Net Income	111	65	85
Changes in Operating Assets and Liabilities, net	-53	14	-132
Net Cash From Investing Activities	-12	32	-78
Net Cash From Continuing Investing Activities	-12	32	-78
Purchase of Property, Plant & Equipment	-30	-73	-45
Acquisitions	0.00	0.00	-57
Purchase of Investments	0.00	0.00	-103
Divestitures	8.80	0.00	0.00
Sale and/or Maturity of Investments	9.00	105	128
Net Cash From Financing Activities	-7.40	153	-8.00
Net Cash From Continuing Financing Activities	-7.40	153	-8.00
Repayment of Debt	-120	-42	-0.70
Issuance of Debt	120	80	0.00
Issuance of Common Equity	5.90	124	6.30
Other Financing Activities, net	-14	-9.00	-14
Effect of Exchange Rate Changes	-1.00	0.60	-0.60

This table details how cash moves in and out of Myriad Genetics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	2.10	8.60	-4.40	-35	56	-28	50	-3.30	-44	4.50
Net Cash From Operating Activities	6.60	0.70	2.60	-19	-55	-22	-0.90	-33	-7.30	-2.80
Net Cash From Continuing Operating Activities	6.60	0.70	2.60	-19	-55	-22	-0.90	-33	-7.30	-2.80
Net Income / (Loss) Continuing Operations	-43	-22	-37	-26	-31	-61	-116	-55	-42	-35
Consolidated Net Income / (Loss)	-43	-22	-37	-26	-31	-61	-116	-55	-42	-35
Depreciation Expense	15	16	15	16	15	14	13	19	14	13
Non-Cash Adjustments To Reconcile Net Income	58	15	28	10	8.00	15	19	24	27	21
Changes in Operating Assets and Liabilities, net	-23	-8.20	-3.30	-19	-58	11	83	-22	-5.60	-1.70
Net Cash From Investing Activities	-5.90	7.50	-6.40	-7.10	-12	-2.50	12	35	-36	11
Net Cash From Continuing Investing Activities	-5.90	7.50	-6.40	-7.10	-12	-2.50	12	35	-36	11
Purchase of Property, Plant & Equipment	-5.90	-6.30	-8.90	-8.60	-14	-18	-19	-24	-15	-18
Net Cash From Financing Activities	2.10	-3.10	2.40	-8.80	122	-2.50	38	-4.90	-2.10	-3.60
Net Cash From Continuing Financing Activities	2.10	-3.10	2.40	-8.80	122	-2.50	38	-4.90	-2.10	-3.60
Repayment of Debt	-20	-20	-20	-60	-40	-0.20	-1.40	0.00	-	-0.70
Issuance of Debt	20	20	20	60	40	-	40	0.00	-	-
Issuance of Common Equity	2.90	-	-	-	124	-	-	-	2.40	0.90
Other Financing Activities, net	-1.30	-3.10	-0.60	-8.80	-1.60	-2.30	-0.20	-4.90	-4.50	-3.80
Effect of Exchange Rate Changes	-0.70	1.20	-0.70	-0.80	0.70	-0.60	0.30	0.20	0.70	-0.50

This table presents Myriad Genetics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	1,028	1,147	1,199
Total Current Assets	298	314	275
Cash & Equivalents	102	132	57
Short-Term Investments	0.00	8.80	58
Accounts Receivable	121	114	102
Inventories, net	28	22	20
Prepaid Expenses	31	19	20
Current Deferred & Refundable Income Taxes	16	17	18
Plant, Property, & Equipment, net	117	119	83
Total Noncurrent Assets	612	714	841
Goodwill	286	287	287
Intangible Assets	262	350	380
Other Noncurrent Operating Assets	64	77	119
Total Liabilities & Shareholders' Equity	1,028	1,147	1,199
Total Liabilities	327	363	313
Total Current Liabilities	164	156	137
Accounts Payable	32	26	29
Accrued Expenses	119	114	94
Other Current Liabilities	13	16	14
Total Noncurrent Liabilities	162	207	176
Long-Term Debt	40	39	0.00
Noncurrent Deferred & Payable Income Tax Liabilities	33	30	27
Other Noncurrent Operating Liabilities	90	139	149
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	701	783	886
Total Preferred & Common Equity	701	783	886
Total Common Equity	701	783	886
Common Stock	1,459	1,416	1,261
Retained Earnings	-757	-630	-366
Accumulated Other Comprehensive Income / (Loss)	-0.80	-3.70	-8.90

This table presents Myriad Genetics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	1,081	1,085	1,111	1,149	1,187	1,169	1,212
Total Current Assets	293	292	290	265	294	262	352
Cash & Equivalents	100	92	97	76	103	54	111
Short-Term Investments	0.00	4.90	7.40	10	19	25	83
Accounts Receivable	126	118	118	115	112	119	102
Inventories, net	26	26	25	25	23	22	20
Prepaid Expenses	24	22	25	21	21	24	20
Current Deferred & Refundable Income Taxes	17	18	18	18	18	18	18
Plant, Property, & Equipment, net	115	116	119	121	112	96	68
Total Noncurrent Assets	673	677	702	763	781	811	792
Goodwill	286	286	287	287	287	287	237
Intangible Assets	313	320	341	357	359	369	371
Other Noncurrent Operating Assets	74	71	74	120	129	125	119
Total Liabilities & Shareholders' Equity	1,081	1,085	1,111	1,149	1,187	1,169	1,212
Total Liabilities	350	345	351	466	452	334	295
Total Current Liabilities	154	149	146	209	221	143	129
Accounts Payable	30	33	33	34	40	37	30
Accrued Expenses	111	98	99	158	164	92	85
Other Current Liabilities	14	13	14	18	17	15	14
Total Noncurrent Liabilities	195	196	204	256	231	191	166
Long-Term Debt	39	39	39	39	38	-	-
Noncurrent Deferred & Payable Income Tax Liabilities	31	31	31	32	33	33	38
Other Noncurrent Operating Liabilities	125	126	135	186	160	158	128
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	732	741	760	683	735	835	917
Total Preferred & Common Equity	732	741	760	683	735	835	917
Total Common Equity	732	741	760	683	735	835	917
Common Stock	1,446	1,437	1,420	1,287	1,278	1,264	1,252
Retained Earnings	-714	-692	-656	-598	-537	-421	-324
Accumulated Other Comprehensive Income / (Loss)	-0.10	-4.00	-4.20	-5.30	-5.40	-7.40	-11

This table displays calculated financial ratios and metrics derived from Myriad Genetics' official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	11.21%	11.03%	-1.77%
EBITDA Growth	67.55%	-116.04%	-852.59%
EBIT Growth	53.25%	-87.00%	-173.44%
NOPAT Growth	52.02%	-83.07%	26.19%
Net Income Growth	51.65%	-135.09%	-311.76%
EPS Growth	55.66%	-128.78%	-297.14%
Operating Cash Flow Growth	92.16%	-4.33%	-671.51%
Free Cash Flow Firm Growth	69.66%	40.75%	-205.97%
Invested Capital Growth	-6.24%	-4.93%	25.63%
Revenue Q/Q Growth	1.70%	2.56%	2.57%
EBITDA Q/Q Growth	-12.92%	14.81%	-11.07%
EBIT Q/Q Growth	-5.79%	7.13%	-6.95%
NOPAT Q/Q Growth	-6.65%	7.48%	-6.92%
Net Income Q/Q Growth	-9.74%	4.05%	-44.89%
EPS Q/Q Growth	-10.16%	5.36%	-47.87%
Operating Cash Flow Q/Q Growth	87.57%	-74.65%	2.03%
Free Cash Flow Firm Q/Q Growth	62.20%	16.23%	-25.68%
Invested Capital Q/Q Growth	-4.85%	7.11%	8.93%
Profitability Metrics	-	-	-
Gross Margin	69.89%	68.64%	70.22%
EBITDA Margin	-7.31%	-25.04%	-12.87%
Operating Margin	-14.74%	-34.17%	-20.73%
EBIT Margin	-14.61%	-34.76%	-20.64%
Profit (Net Income) Margin	-15.20%	-34.96%	-16.51%
Tax Burden Percent	103.08%	100.42%	79.66%
Interest Burden Percent	100.90%	100.15%	100.43%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-13.11%	-25.80%	-15.31%
ROIC Less NNEP Spread (ROIC-NNEP)	36.35%	35.30%	-10.52%
Return on Net Nonoperating Assets (RNNOA)	-4.05%	-5.75%	3.22%
Return on Equity (ROE)	-17.15%	-31.55%	-12.08%
Cash Return on Invested Capital (CROIC)	-6.66%	-20.74%	-38.03%
Operating Return on Assets (OROA)	-11.26%	-22.33%	-11.11%
Return on Assets (ROA)	-11.71%	-22.45%	-8.89%
Return on Common Equity (ROCE)	-17.15%	-31.55%	-12.08%
Return on Equity Simple (ROE_SIMPLE)	-18.16%	-33.62%	-12.64%
Net Operating Profit after Tax (NOPAT)	-86	-180	-98
NOPAT Margin	-10.32%	-23.92%	-14.51%
Net Nonoperating Expense Percent (NNEP)	-49.46%	-61.10%	-4.79%
Return On Investment Capital (ROIC_SIMPLE)	-11.67%	-21.93%	-11.11%
Cost of Revenue to Revenue	30.11%	31.36%	29.78%
SG&A Expenses to Revenue	32.94%	37.67%	36.54%
R&D to Revenue	13.54%	11.78%	12.59%
Operating Expenses to Revenue	84.63%	102.81%	90.95%
Earnings before Interest and Taxes (EBIT)	-122	-262	-140
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-61	-189	-87
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	1.78	2.01	1.33
Price to Tangible Book Value (P/TBV)	8.19	10.75	5.36
Price to Revenue (P/Rev)	1.49	2.09	1.73
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.86	2.16	1.41
Enterprise Value to Revenue (EV/Rev)	1.42	1.95	1.48
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.06	0.05	0.00
Long-Term Debt to Equity	0.06	0.05	0.00
Financial Leverage	-0.11	-0.16	-0.31
Leverage Ratio	1.46	1.41	1.36
Compound Leverage Factor	1.48	1.41	1.37
Debt to Total Capital	5.35%	4.69%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	5.35%	4.69%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	94.65%	95.31%	100.00%
Debt to EBITDA	-0.65	-0.20	0.00
Net Debt to EBITDA	1.03	0.54	0.00
Long-Term Debt to EBITDA	-0.65	-0.20	0.00
Debt to NOPAT	-0.46	-0.21	0.00
Net Debt to NOPAT	0.73	0.57	0.00
Long-Term Debt to NOPAT	-0.46	-0.21	0.00
Altman Z-Score	1.84	1.90	2.15
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	1.82	2.01	2.00
Quick Ratio	1.36	1.64	1.58
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-44	-145	-245
Operating Cash Flow to CapEx	-29.29%	-151.30%	-234.66%
Free Cash Flow to Firm to Interest Expense	-15.70	-49.96	-76.41
Operating Cash Flow to Interest Expense	-3.11	-38.24	-33.22
Operating Cash Flow Less CapEx to Interest Expense	-13.71	-63.52	-47.38
Efficiency Ratios	-	-	-
Asset Turnover	0.77	0.64	0.54
Accounts Receivable Turnover	7.11	6.98	7.03
Inventory Turnover	10.19	11.22	11.41
Fixed Asset Turnover	7.09	7.44	10.69
Accounts Payable Turnover	8.68	8.65	6.92
Days Sales Outstanding (DSO)	51.31	52.31	51.89
Days Inventory Outstanding (DIO)	35.82	32.53	31.98
Days Payable Outstanding (DPO)	42.04	42.19	52.76
Cash Conversion Cycle (CCC)	45.09	42.65	31.11
Capital & Investment Metrics	-	-	-
Invested Capital	638	681	716
Invested Capital Turnover	1.27	1.08	1.06
Increase / (Decrease) in Invested Capital	-43	-35	146
Enterprise Value (EV)	1,185	1,471	1,006
Market Capitalization	1,248	1,573	1,176
Book Value per Share	$7.70	$9.53	$10.93
Tangible Book Value per Share	$1.67	$1.78	$2.71
Total Capital	741	822	886
Total Debt	40	39	0.00
Total Long-Term Debt	40	39	0.00
Net Debt	-63	-102	-170
Capital Expenditures (CapEx)	30	73	45
Debt-free, Cash-free Net Working Capital (DFCFNWC)	32	17	23
Debt-free Net Working Capital (DFNWC)	134	158	137
Net Working Capital (NWC)	134	158	137
Net Nonoperating Expense (NNE)	41	83	14
Net Nonoperating Obligations (NNO)	-63	-102	-170
Total Depreciation and Amortization (D&A)	61	73	53
Debt-free, Cash-free Net Working Capital to Revenue	3.76%	2.23%	3.32%
Debt-free Net Working Capital to Revenue	15.99%	20.94%	20.25%
Net Working Capital to Revenue	15.99%	20.94%	20.25%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($1.41)	($3.18)	($1.39)
Adjusted Weighted Average Basic Shares Outstanding	90.60M	82.80M	80.60M
Adjusted Diluted Earnings per Share	($1.41)	($3.18)	($1.39)
Adjusted Weighted Average Diluted Shares Outstanding	90.60M	82.80M	80.60M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	91.31M	89.87M	81.22M
Normalized Net Operating Profit after Tax (NOPAT)	-47	-180	-87
Normalized NOPAT Margin	-5.57%	-23.92%	-12.76%
Pre Tax Income Margin	-14.74%	-34.81%	-20.73%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-43.71	-90.28	-43.75
NOPAT to Interest Expense	-30.88	-62.13	-30.76
EBIT Less CapEx to Interest Expense	-54.32	-115.55	-57.91
NOPAT Less CapEx to Interest Expense	-41.48	-87.41	-44.91
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Myriad Genetics' official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	7.12%	11.15%	15.26%	11.59%	10.57%	22.70%	2.34%	9.88%	10.57%	-6.52%
EBITDA Growth	-41.18%	88.87%	78.89%	69.16%	55.84%	-48.73%	-2,041.67%	-165.08%	-29.19%	-157.19%
EBIT Growth	-20.87%	65.79%	68.30%	50.76%	38.51%	-36.63%	-555.93%	-106.25%	-21.11%	-209.34%
NOPAT Growth	-24.52%	66.72%	67.90%	46.55%	39.85%	-33.56%	-538.76%	-103.91%	-21.11%	36.22%
Net Income Growth	-36.22%	63.95%	68.39%	52.47%	26.24%	-74.64%	-723.40%	-166.83%	-456.58%	-242.68%
EPS Growth	-38.24%	68.00%	71.13%	56.72%	34.62%	-74.42%	-688.89%	-157.69%	-642.86%	-243.33%
Operating Cash Flow Growth	112.07%	103.17%	388.89%	43.98%	-649.32%	-689.29%	98.19%	28.60%	23.16%	92.88%
Free Cash Flow Firm Growth	13.59%	-142.72%	10.13%	108.02%	107.29%	84.87%	8.84%	-171.45%	-154.69%	-136.52%
Invested Capital Growth	-6.24%	5.54%	4.61%	-4.37%	-4.93%	-3.32%	-2.71%	18.86%	25.63%	18.47%
Revenue Q/Q Growth	-1.27%	0.85%	4.60%	2.85%	2.45%	4.58%	1.27%	1.91%	13.68%	-12.77%
EBITDA Q/Q Growth	-361.54%	76.04%	-110.68%	39.41%	63.60%	54.57%	-207.78%	13.25%	-22.61%	-554.17%
EBIT Q/Q Growth	-86.54%	43.48%	-41.54%	19.00%	47.20%	47.63%	-119.89%	-1.15%	-17.30%	-151.41%
NOPAT Q/Q Growth	-95.50%	45.21%	-30.82%	11.15%	47.75%	47.14%	-117.82%	0.00%	-16.00%	-152.81%
Net Income Q/Q Growth	-92.31%	39.78%	-41.15%	16.67%	49.10%	47.20%	-112.25%	-29.31%	-20.51%	-148.94%
EPS Q/Q Growth	-95.83%	41.46%	-41.38%	14.71%	54.67%	47.18%	-111.94%	-28.85%	-20.93%	-138.89%
Operating Cash Flow Q/Q Growth	842.86%	-73.08%	113.98%	66.00%	-147.51%	-2,355.56%	97.29%	-354.79%	-160.71%	94.37%
Free Cash Flow Firm Q/Q Growth	130.75%	11.11%	-554.81%	-8.63%	165.71%	67.09%	59.41%	16.92%	-36.30%	-98.34%
Invested Capital Q/Q Growth	-4.85%	-0.71%	-2.71%	2.00%	7.11%	-1.58%	-11.06%	1.40%	8.93%	-0.96%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	71.65%	70.23%	69.55%	68.05%	68.67%	69.98%	68.50%	67.33%	69.69%	67.77%
EBITDA Margin	-11.40%	-2.44%	-10.26%	-5.09%	-8.65%	-24.34%	-56.02%	-18.43%	-21.65%	-20.08%
Operating Margin	-18.57%	-9.38%	-17.26%	-13.80%	-15.97%	-31.32%	-61.96%	-28.81%	-29.36%	-28.77%
EBIT Margin	-18.42%	-9.75%	-17.40%	-12.86%	-16.33%	-31.68%	-63.27%	-29.14%	-29.36%	-28.45%
Profit (Net Income) Margin	-20.18%	-10.36%	-17.35%	-12.86%	-15.87%	-31.94%	-63.27%	-30.19%	-23.79%	-22.44%
Tax Burden Percent	108.42%	104.25%	98.66%	100.39%	96.59%	100.16%	100.00%	103.99%	81.19%	79.41%
Interest Burden Percent	101.03%	101.92%	101.09%	99.62%	100.62%	100.66%	100.00%	99.62%	99.81%	99.33%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-16.50%	-8.28%	-14.67%	-10.53%	-12.06%	-24.90%	-46.29%	-20.96%	-21.68%	-21.98%
ROIC Less NNEP Spread (ROIC-NNEP)	1.81%	6.63%	-0.22%	-3.12%	-5.28%	-12.38%	-26.72%	-12.85%	-19.65%	-20.91%
Return on Net Nonoperating Assets (RNNOA)	-0.20%	-0.51%	0.02%	0.34%	0.86%	2.37%	5.92%	3.23%	6.02%	7.46%
Return on Equity (ROE)	-16.71%	-8.78%	-14.65%	-10.19%	-11.20%	-22.53%	-40.37%	-17.73%	-15.66%	-14.51%
Cash Return on Invested Capital (CROIC)	-6.66%	-17.80%	-21.03%	-18.51%	-20.74%	-26.75%	-25.38%	-34.74%	-38.03%	-32.10%
Operating Return on Assets (OROA)	-14.20%	-7.20%	-12.29%	-8.73%	-10.49%	-19.71%	-36.89%	-16.70%	-15.81%	-14.77%
Return on Assets (ROA)	-15.55%	-7.65%	-12.25%	-8.73%	-10.19%	-19.87%	-36.89%	-17.30%	-12.81%	-11.65%
Return on Common Equity (ROCE)	-16.71%	-8.78%	-14.65%	-10.19%	-11.20%	-22.53%	-40.37%	-17.73%	-15.66%	-14.52%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-15.85%	-20.96%	-30.87%	0.00%	-40.15%	-33.76%	-17.50%	0.00%	-8.43%
Net Operating Profit after Tax (NOPAT)	-27	-14	-26	-20	-22	-42	-80	-37	-37	-32
NOPAT Margin	-13.00%	-6.56%	-12.08%	-9.66%	-11.18%	-21.92%	-43.37%	-20.17%	-20.55%	-20.14%
Net Nonoperating Expense Percent (NNEP)	-18.32%	-14.90%	-14.45%	-7.41%	-6.78%	-12.53%	-19.58%	-8.10%	-2.03%	-1.07%
Return On Investment Capital (ROIC_SIMPLE)	-3.70%	-1.82%	-3.28%	-2.45%	-2.67%	-5.83%	-10.29%	-4.38%	-4.13%	-3.44%
Cost of Revenue to Revenue	28.35%	29.77%	30.45%	31.95%	31.33%	30.02%	31.50%	32.67%	30.32%	32.23%
SG&A Expenses to Revenue	-70.61%	65.21%	68.51%	69.54%	-73.65%	70.92%	76.68%	83.72%	-67.66%	83.44%
R&D to Revenue	15.62%	13.36%	12.81%	12.31%	10.68%	12.51%	11.55%	12.42%	13.16%	13.11%
Operating Expenses to Revenue	90.22%	79.61%	86.81%	81.85%	84.64%	101.30%	130.46%	96.14%	99.04%	96.55%
Earnings before Interest and Taxes (EBIT)	-39	-21	-37	-26	-32	-61	-116	-53	-52	-45
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-24	-5.20	-22	-10	-17	-47	-103	-33	-39	-31
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.78	3.40	2.99	2.31	2.01	1.92	2.57	2.26	1.33	1.68
Price to Tangible Book Value (P/TBV)	8.19	18.72	16.44	13.27	10.75	32.67	21.19	10.56	5.36	4.97
Price to Revenue (P/Rev)	1.49	3.02	2.76	2.26	2.09	1.79	2.70	2.72	1.73	2.33
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.86	3.62	3.19	2.43	2.16	1.99	2.79	2.45	1.41	1.95
Enterprise Value to Revenue (EV/Rev)	1.42	2.95	2.69	2.18	1.95	1.72	2.58	2.56	1.48	1.93
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.06	0.05	0.05	0.05	0.05	0.06	0.05	0.00	0.00	0.00
Long-Term Debt to Equity	0.06	0.05	0.05	0.05	0.05	0.06	0.05	0.00	0.00	0.00
Financial Leverage	-0.11	-0.08	-0.10	-0.11	-0.16	-0.19	-0.22	-0.25	-0.31	-0.36
Leverage Ratio	1.46	1.58	1.54	1.43	1.41	1.48	1.42	1.36	1.36	1.35
Compound Leverage Factor	1.48	1.61	1.56	1.42	1.41	1.49	1.42	1.35	1.36	1.34
Debt to Total Capital	5.35%	5.06%	4.98%	4.85%	4.69%	5.33%	4.96%	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	5.35%	5.06%	4.98%	4.85%	4.69%	5.33%	4.96%	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	94.65%	94.94%	95.02%	95.15%	95.31%	94.67%	95.04%	100.00%	100.00%	100.00%
Debt to EBITDA	-0.65	-0.72	-0.41	-0.22	-0.20	-0.17	-0.19	0.00	0.00	0.00
Net Debt to EBITDA	1.03	1.12	0.61	0.37	0.54	0.22	0.43	0.00	0.00	0.00
Long-Term Debt to EBITDA	-0.65	-0.72	-0.41	-0.22	-0.20	-0.17	-0.19	0.00	0.00	0.00
Debt to NOPAT	-0.46	-0.48	-0.36	-0.24	-0.21	-0.20	-0.21	0.00	0.00	0.00
Net Debt to NOPAT	0.73	0.75	0.54	0.40	0.57	0.25	0.49	0.00	0.00	0.00
Long-Term Debt to NOPAT	-0.46	-0.48	-0.36	-0.24	-0.21	-0.20	-0.21	0.00	0.00	0.00
Altman Z-Score	2.11	4.20	3.75	2.95	2.56	1.49	2.22	3.45	2.39	3.40
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-0.01%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.82	1.90	1.96	1.99	2.01	1.27	1.33	1.83	2.00	2.73
Quick Ratio	1.36	1.46	1.44	1.52	1.64	0.96	1.06	1.38	1.58	2.29
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	15	-49	-55	12	13	-20	-62	-152	-183	-134
Operating Cash Flow to CapEx	111.86%	11.11%	29.21%	-216.28%	-405.19%	-126.29%	-4.79%	-141.28%	-50.00%	-15.82%
Free Cash Flow to Firm to Interest Expense	21.61	-61.50	-69.19	24.34	14.80	-20.27	-123.18	-303.48	-202.93	-167.50
Operating Cash Flow to Interest Expense	9.43	0.88	3.25	-37.20	-60.78	-22.10	-1.80	-66.40	-8.11	-3.50
Operating Cash Flow Less CapEx to Interest Expense	1.00	-7.00	-7.88	-54.40	-75.78	-39.60	-39.40	-113.40	-24.33	-25.63
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.77	0.74	0.71	0.68	0.64	0.62	0.58	0.57	0.54	0.52
Accounts Receivable Turnover	7.11	6.84	6.99	6.53	6.98	6.76	6.31	6.29	7.03	6.76
Inventory Turnover	10.19	9.91	10.21	10.41	11.22	10.22	11.68	11.40	11.41	10.15
Fixed Asset Turnover	7.09	6.98	7.03	7.21	7.44	7.80	8.48	9.78	10.69	11.93
Accounts Payable Turnover	8.68	8.00	6.79	6.94	8.65	7.20	7.20	6.70	6.92	8.56
Days Sales Outstanding (DSO)	51.31	53.38	52.21	55.91	52.31	54.02	57.84	58.00	51.89	54.03
Days Inventory Outstanding (DIO)	35.82	36.84	35.74	35.05	32.53	35.70	31.26	32.01	31.98	35.95
Days Payable Outstanding (DPO)	42.04	45.61	53.75	52.57	42.19	50.72	50.72	54.44	52.76	42.64
Cash Conversion Cycle (CCC)	45.09	44.62	34.20	38.39	42.65	39.01	38.38	35.58	31.11	47.34
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	638	671	676	694	681	636	646	726	716	657
Invested Capital Turnover	1.27	1.26	1.21	1.09	1.08	1.14	1.07	1.04	1.06	1.09
Increase / (Decrease) in Invested Capital	-43	35	30	-32	-35	-22	-18	115	146	103
Enterprise Value (EV)	1,185	2,427	2,155	1,687	1,471	1,266	1,801	1,778	1,006	1,279
Market Capitalization	1,248	2,488	2,214	1,752	1,573	1,313	1,890	1,887	1,176	1,539
Book Value per Share	$7.70	$8.06	$8.18	$8.45	$9.53	$8.35	$9.01	$10.28	$10.93	$11.37
Tangible Book Value per Share	$1.67	$1.46	$1.49	$1.47	$1.78	$0.49	$1.09	$2.20	$2.71	$3.84
Total Capital	741	771	779	799	822	722	774	835	886	917
Total Debt	40	39	39	39	39	39	38	0.00	0.00	0.00
Total Long-Term Debt	40	39	39	39	39	39	38	0.00	0.00	0.00
Net Debt	-63	-61	-59	-66	-102	-48	-89	-109	-170	-259
Capital Expenditures (CapEx)	5.90	6.30	8.90	8.60	14	18	19	24	15	18
Debt-free, Cash-free Net Working Capital (DFCFNWC)	32	39	45	40	17	-30	-48	40	23	30
Debt-free Net Working Capital (DFNWC)	134	139	143	144	158	56	73	118	137	223
Net Working Capital (NWC)	134	139	143	144	158	56	73	118	137	223
Net Nonoperating Expense (NNE)	15	8.10	11	6.47	9.22	19	37	18	5.76	3.60
Net Nonoperating Obligations (NNO)	-63	-61	-65	-66	-102	-48	-89	-109	-170	-259
Total Depreciation and Amortization (D&A)	15	16	15	16	15	14	13	19	14	13
Debt-free, Cash-free Net Working Capital to Revenue	3.76%	4.74%	5.66%	5.15%	2.23%	-4.11%	-6.93%	5.70%	3.32%	4.54%
Debt-free Net Working Capital to Revenue	15.99%	16.87%	17.79%	18.63%	20.94%	7.64%	10.47%	17.03%	20.25%	33.75%
Net Working Capital to Revenue	15.99%	16.87%	17.79%	18.63%	20.94%	7.64%	10.47%	17.03%	20.25%	33.75%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.47)	($0.24)	($0.41)	($0.29)	($0.34)	($0.75)	($1.42)	($0.67)	($0.52)	($0.43)
Adjusted Weighted Average Basic Shares Outstanding	90.60M	90.90M	90.60M	89.90M	82.80M	81.90M	81.70M	81.30M	80.60M	80.70M
Adjusted Diluted Earnings per Share	($0.47)	($0.24)	($0.41)	($0.29)	($0.34)	($0.75)	($1.42)	($0.67)	($0.52)	($0.43)
Adjusted Weighted Average Diluted Shares Outstanding	90.60M	90.90M	90.60M	89.90M	82.80M	81.90M	81.70M	81.30M	80.60M	80.70M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	91.31M	91.04M	90.82M	90.51M	89.87M	82.20M	81.88M	81.56M	81.22M	81.03M
Normalized Net Operating Profit after Tax (NOPAT)	-27	-12	-17	-20	-22	-18	-25	-37	-32	-32
Normalized NOPAT Margin	-13.00%	-5.84%	-8.24%	-9.66%	-11.18%	-9.41%	-13.81%	-20.17%	-18.11%	-20.14%
Pre Tax Income Margin	-18.61%	-9.94%	-17.59%	-12.81%	-16.43%	-31.89%	-63.27%	-29.03%	-29.30%	-28.26%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-55.43	-26.00	-46.00	-52.00	-35.67	-60.80	-232.20	-105.60	-58.00	-55.63
NOPAT to Interest Expense	-39.10	-17.50	-31.94	-39.06	-24.42	-42.07	-159.18	-73.08	-40.60	-39.38
EBIT Less CapEx to Interest Expense	-63.86	-33.88	-57.13	-69.20	-50.67	-78.30	-269.80	-152.60	-74.22	-77.75
NOPAT Less CapEx to Interest Expense	-47.53	-25.38	-43.06	-56.26	-39.42	-59.57	-196.78	-120.08	-56.82	-61.50
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About Myriad Genetics' Financials

When does Myriad Genetics's fiscal year end?

According to the most recent income statement we have on file, Myriad Genetics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Myriad Genetics' net income changed over the last 2 years?

Myriad Genetics' net income appears to be on an upward trend, with a most recent value of -$127.30 million in 2024, rising from -$112 million in 2022. The previous period was -$263.30 million in 2023. Check out Myriad Genetics' forecast to explore projected trends and price targets.

What is Myriad Genetics's operating income?

Myriad Genetics's total operating income in 2024 was -$123.50 million, based on the following breakdown:

Total Gross Profit: $585.40 million
Total Operating Expenses: $708.90 million

How has Myriad Genetics revenue changed over the last 2 years?

Over the last 2 years, Myriad Genetics' total revenue changed from $678.40 million in 2022 to $837.60 million in 2024, a change of 23.5%.

How much debt does Myriad Genetics have?

Myriad Genetics' total liabilities were at $326.50 million at the end of 2024, a 10.1% decrease from 2023, and a 4.3% increase since 2022.

How much cash does Myriad Genetics have?

In the past 2 years, Myriad Genetics' cash and equivalents has ranged from $56.90 million in 2022 to $132.10 million in 2023, and is currently $102.40 million as of their latest financial filing in 2024.

How has Myriad Genetics' book value per share changed over the last 2 years?

Over the last 2 years, Myriad Genetics' book value per share changed from 10.93 in 2022 to 7.70 in 2024, a change of -29.5%.

Related Companies

This page (NASDAQ:MYGN) was last updated on 5/29/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Myriad Genetics (MYGN) Financials

Frequently Asked Questions About Myriad Genetics' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Myriad Genetics (MYGN) Financials

Annual Income Statements for Myriad Genetics

Quarterly Income Statements for Myriad Genetics

Annual Cash Flow Statements for Myriad Genetics

Quarterly Cash Flow Statements for Myriad Genetics

Annual Balance Sheets for Myriad Genetics

Quarterly Balance Sheets for Myriad Genetics

Annual Metrics And Ratios for Myriad Genetics

Quarterly Metrics And Ratios for Myriad Genetics

Frequently Asked Questions About Myriad Genetics' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools